Development of n-tert-(butyl)hydroxylamine (ntbuha) as a therapeutic agent for treating infantile neuronal ceroid lipofuscinosis (incl)
Ended Project Grant Awarded Last action
- Award ID
- R43NS100233
- Recipient
-
Circumvent Pharmaceuticals Inc. UEI Y14DQ5VD56A7
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $198,694
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- Portland, OR 97239, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$96 | |
| Original award | $198,790 |
Quick answers
Who received award R43NS100233?
R43NS100233 was awarded to Circumvent Pharmaceuticals Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on March 1, 2017.
How much is award R43NS100233 worth?
$198,694 has been obligated on R43NS100233.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award